[go: up one dir, main page]

MX2007002393A - Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6). - Google Patents

Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).

Info

Publication number
MX2007002393A
MX2007002393A MX2007002393A MX2007002393A MX2007002393A MX 2007002393 A MX2007002393 A MX 2007002393A MX 2007002393 A MX2007002393 A MX 2007002393A MX 2007002393 A MX2007002393 A MX 2007002393A MX 2007002393 A MX2007002393 A MX 2007002393A
Authority
MX
Mexico
Prior art keywords
substituted indole
receptor modulators
indole compounds
medicaments
preparation
Prior art date
Application number
MX2007002393A
Other languages
English (en)
Inventor
Ramon Merce Vidal
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2007002393A publication Critical patent/MX2007002393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente intencion se refiere a compuestos indolicos sustituidos de formula general I (ver formula (I)), un proceso para su preparacion, medicamentos que comprenden los compuestos indolicos sustituidos asi como tambien el uso de compuestos indolicos sustituidos para la preparacion de medicamentos, los cuales son adecuados por ejemplo para la profilaxis y/o tratamiento de trastornos o enfermedades que estan mediados/as al menos parcialmente por los receptores 5-HT6.
MX2007002393A 2004-08-30 2005-08-30 Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6). MX2007002393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04020535A EP1632491A1 (en) 2004-08-30 2004-08-30 Substituted indole compounds and their use as 5-HT6 receptor modulators
PCT/EP2005/009459 WO2006024535A1 (en) 2004-08-30 2005-08-30 Substituted indole compounds and their use as 5-ht6 receptor modulators

Publications (1)

Publication Number Publication Date
MX2007002393A true MX2007002393A (es) 2007-08-14

Family

ID=34926351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002393A MX2007002393A (es) 2004-08-30 2005-08-30 Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).

Country Status (7)

Country Link
US (1) US20070213326A1 (es)
EP (3) EP1632491A1 (es)
JP (1) JP2008511575A (es)
CN (1) CN101068809A (es)
CA (1) CA2577925A1 (es)
MX (1) MX2007002393A (es)
WO (1) WO2006024535A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
WO2008050821A1 (en) * 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
DE102007035334A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
ATE495737T1 (de) * 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
EP2036888A1 (en) * 2007-09-17 2009-03-18 Laboratorios del Dr. Esteve S.A. Naphthyl-substituted sulfonamides
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
EP2116547A1 (en) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
EP2116546A1 (en) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
KR101941004B1 (ko) 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
WO2023044556A1 (en) * 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Aminated psilocybin derivatives and methods of using
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
WO2023114325A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Constrained amine psychoplastogens and uses thereof
JP2025502615A (ja) * 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
KR20240150418A (ko) * 2021-12-15 2024-10-15 델릭스 테라퓨틱스, 인크. 융합된 피롤리딘 사이코플라스토겐 및 그의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
CA948639A (en) * 1971-01-21 1974-06-04 Polaroid Corporation Indole phthalein indicator dyes
FR2354766A1 (fr) 1976-06-17 1978-01-13 Labaz Derives n-aminoalkyles d'indole et procedes pour les preparer
JPS62503194A (ja) * 1985-07-03 1987-12-17 ポラロイド　コ−ポレ−シヨン カラー拡散転写写真フィルム単位
US4615966A (en) * 1985-07-03 1986-10-07 Polaroid Corporation Color transfer photographic processes and products with indole phthalein filter dyes
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
WO1998022457A1 (en) * 1996-11-19 1998-05-28 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
KR100894189B1 (ko) * 2001-03-29 2009-04-22 일라이 릴리 앤드 캄파니 5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민
US6541177B1 (en) * 2001-04-16 2003-04-01 Polaroid Corporatiion Diffusion transfer photographic film unit
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
RU2005138147A (ru) * 2003-05-09 2007-06-27 Лабораториос Дель Др. Эстеве С.А. (Es) Применение сульфонамидных производных для изготовления лекарственного средства, предназначенного для профилактики и/или лечения нарушений потребления пищи
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222828B1 (es) * 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
US7167043B2 (en) * 2003-11-24 2007-01-23 International Rectifier Corporation Decoupling circuit for co-packaged semiconductor devices
AU2005226759A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.

Also Published As

Publication number Publication date
CA2577925A1 (en) 2006-03-09
EP1632491A1 (en) 2006-03-08
JP2008511575A (ja) 2008-04-17
EP1786804A1 (en) 2007-05-23
WO2006024535A1 (en) 2006-03-09
CN101068809A (zh) 2007-11-07
EP2308871A1 (en) 2011-04-13
US20070213326A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
TW200510301A (en) Novel compounds
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200407305A (en) Novel compounds
MX2009006882A (es) Derivados de indol como agonistas del receptor s1p1.
UA99620C2 (en) Pyridyl piperidine orexin receptor antagonists
SE0202241D0 (sv) Novel Compounds
SE0303180D0 (sv) Novel compounds
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
HK1132742A1 (en) Substituted oxindole derivative and its use as a vasopressin receptor modulator
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal